drugset / Trial / NCT01973335
Acetazolamide and Spironolactone to Increase Natriuresis in Congestive Heart Failure
Phase 4
Completed
34 enrolled
Hasselt University
Universitaire Ziekenhuizen KU Leuven · collabZiekenhuis Oost-Limburg · collab
RandomizedFactorialTriple-blindTreatment
Summary
This study has two primary objectives: 1. To compare combination therapy with acetazolamide and low-dose loop diuretics versus high-dose loop diuretics (standard of care) in patients with acute decompensated heart failure at high risk for diuretic resistance. 2. To demonstrate the safety and efficacy of upfront therapy with spironolactone in addition to loop diuretic therapy in patients with acute decompensated heart failure at high risk for diuretic resistance.
Timeline
- Start
- 2013-11
- Primary completion
- 2017-04
- Completion
- 2017-10
Publications
- Results Verbrugge FH, Martens P, Ameloot K, Haemels V, Penders J, Dupont M, Tang WHW, Droogne W, Mullens W. Spironolactone to increase natriuresis in congestive heart failure with cardiorenal syndrome. Acta Cardiol. 2019 Apr;74(2):100-107. doi: 10.1080/00015385.2018.1455947. Epub 2018 Mar 27.
- Results Verbrugge FH, Martens P, Ameloot K, Haemels V, Penders J, Dupont M, Tang WHW, Droogne W, Mullens W. Acetazolamide to increase natriuresis in congestive heart failure at high risk for diuretic resistance. Eur J Heart Fail. 2019 Nov;21(11):1415-1422. doi: 10.1002/ejhf.1478. Epub 2019 May 9.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Acetazolamide | Small molecule | 250 mg | Intravenous |
| Subject | Bumetanide | Small molecule | 1 mg | Intravenous |
| Subject | Spironolactone | Small molecule | 25 mg | Oral |